If you’re not a fan of counting drug developers among cannabis pure-plays, then the pot stock with the best chance to reach $1 billion in sales first is U.S. multistate operator (MSO) Curaleaf Holdings (OTC:CURL.F).
Among publicly traded U.S. MSO’s, there’s not a one that has more operational dispensaries than Curaleaf. As of this past week, it had 57 operational dispensaries to go along with 15 cultivation sites and 24 processing centers in 18 total states. As you can imagine, having more operational retail locations gives Curaleaf a leg up on its competition, at least in regard to the race to $1 billion in annual sales.
It’s also important to note that Curaleaf hasn’t had any issue obtaining traditional forms of financing. With its common stock used as collateral for deals, and the company sporting plenty of cash to cover its organic dispensary expansion, financing won’t hinder Curaleaf in the same way it’s slowed down many of its peers.
Curaleaf appears to be on track to bring in $1 billion in revenue by 2022, with a slight chance of this happening by 2021.
Green Thumb Industries
The way I view it, there’s really only one MSO other than Curaleaf that could reach the $1 billion annual sales plateau first, and that’s Green Thumb Industries (OTC:GTBI.F).
Though Trulieve Cannabis has a few…..